Celularity Inc - Ordinary Shares - Class A Stock

$2.96

6.33% day before yesterday

Nasdaq, Jul 25, 10:00 pm CET

ISIN

US1511901050

Symbol

CELU

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Celularity Inc - Ordinary Shares - Class A Stock price

$2.96

-100.94 97.15% 5Y

Nasdaq, Closing price Fri, Jul 25 2025

-0.20 6.33%

ISIN

US1511901050

Symbol

CELU

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$70.9m

Enterprise Value

$112.4m

Net debt

$41.6m

Cash

$740.0k

Shares outstanding

22.6m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

1.3 | 1.1

EV/Sales

2.1 | 1.7

EV/FCF

negative

P/B

8.0

Financial Health

Equity Ratio

6.7%

Return on Equity

-654.9%

ROCE

-48.2%

ROIC

-36.8%

Debt/Equity

4.8

Financials (TTM | estimate)

Revenue

$54.2m | $66.8m

EBITDA

$-36.3m | -

EBIT

$-38.1m | $-101.6m

Net Income

$-57.9m | $-9.7m

Free Cash Flow

$-8.1m

Growth (TTM | estimate)

Revenue

138.1% | 23.3%

EBITDA

-732.8% | -

EBIT

-1,174.0% | -164.8%

Net Income

70.5% | 83.3%

Free Cash Flow

81.3%

EPS

$-2.6

FCF per Share

$-0.4

Short interest

34.2%

Employees

120

Rev per Employee

$450.0k

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

Celularity Inc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Celularity Inc - Ordinary Shares - Class A forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Celularity Inc - Ordinary Shares - Class A forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Celularity Inc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	54 54	138% 138% 100%
- Direct Costs	15 15	6% 6% 28%
Gross Profit	39 39	480% 480% 72%
- Selling and Administrative Expenses	59 59	16% 16% 108%
- Research and Development Expense	17 17	43% 43% 32%
EBITDA	-36 -36	733% 733% -67%
- Depreciation and Amortization	1.76 1.76	20% 20% 3%
EBIT (Operating Income) EBIT	-38 -38	1,174% 1,174% -70%
Net Profit	-58 -58	71% 71% -107%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Celularity Inc - Ordinary Shares - Class A Stock News

Neutral

GlobeNewsWire

●

18 days ago

Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

FLORHAM PARK, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, announced today that it entered into a strategic partnership with Fountain Life, a global leader in science-backed longevity and preventative health company, to supply stem cell therapy prod...

Neutral

GlobeNewsWire

●

26 days ago

Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies

New law goes into effect on July 1st authorizing Florida physicians to provide stem cell therapies to their patients for orthopedics, wound care, and pain management FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today hailed a new Florida law taking effect today that opens the ...

Neutral

GlobeNewsWire

●

about 2 months ago

Celularity Announces Chief Financial Officer Transition

Celularity retains financial and business advisor to provide outsourced accounting and consulting services during the transition period Celularity retains financial and business advisor to provide outsourced accounting and consulting services during the transition period

More Celularity Inc - Ordinary Shares - Class A News

Company Profile

Celularity, Inc. a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The firms CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. It is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. The company is headquartered in Florham Park, NJ.

Head office	United States
CEO	Robert Gordon
Employees	120
Founded	2016
Website	celularity.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now